For research use only. Not for therapeutic Use.
Tavapadon (Cat NO.: I016659) is a selective dopamine D1/D5 receptor partial agonist being developed for Parkinson’s disease and other neurological disorders. By modulating dopamine signaling, it enhances motor function while minimizing side effects associated with traditional dopaminergic therapies. Its unique mechanism provides sustained receptor activation, potentially improving movement control and reducing dyskinesia. With high oral bioavailability and a favorable safety profile, Tavapadon is a promising candidate for treating motor symptoms in Parkinson’s disease, supporting research into novel neuroprotective and symptomatic therapies.
| CAS Number | 1643489-24-0 |
| Molecular Formula | C₁₉H₁₆F₃N₃O₃ |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| IUPAC Name | 1,5-dimethyl-6-[2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyrimidine-2,4-dione |
| InChI | 1S/C19H16F3N3O3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9H,1-3H3,(H,24,26,27) |
| InChIKey | AKQXQLUNFKDZBN-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C |
| Reference | [1]. Young D, et al. D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited DyskinesiaSide Effects. ACS Chem Neurosci. 2020 Feb 19;11(4):560-566. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
